CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 1/2 Dose Escalation and Cohort Expansion Study Evaluating MCLA-158 (Petosemtamab) as Single Agent or in Combination in Advanced Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03526835
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:55.195983+00:00
Published At: 2025-01-29T00:00:00+00:00
Record Updated At: 2025-01-29
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Advanced/Metastatic Solid Tumors", "Colorectal Cancer", "Gastric Cancer", "Gastroesophageal-junction Cancer", "NSCLC", "HNSCC", "Head and Neck Squamous Cell Carcinoma", "Esophageal Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-01-29"
protocolSection.identificationModule.nctId: "NCT03526835"
protocolSection.identificationModule.officialTitle: "Phase 1/2 Dose Escalation and Cohort Expansion Study Evaluating MCLA-158 (Petosemtamab) as Single Agent or in Combination in Advanced Solid Tumors"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.